Actively Recruiting
Study on Treatment Adherence, Persistence, and Effectiveness of PCSK9 Inhibitors for Hypercholesterolemia in Italy
Led by Federico II University · Updated on 2026-01-22
5000
Participants Needed
27
Research Sites
426 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the adherence, persistence, and effectiveness of PCSK9 inhibitors in treating hypercholesterolemia among a real-life Italian population. This observational study focuses on patients receiving these medications to better understand treatment patterns and outcomes outside of controlled clinical trials. Participants in this study are patients with hyperlipidemia who are currently treated with PCSK9 inhibitors, specifically Repatha evolocumab or Praluent alirocumab, administered by injection. The study observes these patients without altering their treatment, collecting data over time to assess how well patients stick to their treatment plans and how effective the medications are. During the study, researchers will gather information every six months about treatment adherence, persistence, and efficacy. They will also monitor safety and analyze results within different patient subgroups. Participation includes regular assessments of medication use and health outcomes, with the study continuing until March 31, 2030.
CONDITIONS
Brief Title
Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
Research Team
P
Pasquale Perrone Filardi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
